Publications by authors named "Yuriko Hamaguchi"

Claim this Profile
I
Inhibitory Effect of Pyra-Metho-Carnil on the Differentiation and Maturation of Macrophages in Normal and Cancer Microenvironments.
Takanori Kitaguchi, Taichi Matsumoto, Kazumasa Yoshida, Yuriko Hamaguchi, Gen Maruta

Anticancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth.
Yuki Tanaka, Chikayo Iwaya, Takako Kawanami, Yuriko Hamaguchi, Tsuyoshi Horikawa

Diabetol Int· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro.
Leona Yamamoto, Shinichi Yamashita, Takashi Nomiyama, Takako Kawanami, Yuriko Hamaguchi

Diabetol Int· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-mobility group box 2 protein is essential for the early phase of adipogenesis.
Hidetaka Morinaga, Yoshimi Muta, Tomoko Tanaka, Makito Tanabe, Yuriko Hamaguchi

Biochem Biophys Res Commun· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet.
Tsuyoshi Horikawa, Takako Kawanami, Yuriko Hamaguchi, Yuki Tanaka, Shotaro Kita

Heliyon· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression.
Toru Shigeoka, Takashi Nomiyama, Takako Kawanami, Yuriko Hamaguchi, Tsuyoshi Horikawa

J Diabetes Investig· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
Shiho Komatsu, Takashi Nomiyama, Tomohiro Numata, Takako Kawanami, Yuriko Hamaguchi

Endocr J· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice.
Hiroyuki Takahashi, Takashi Nomiyama, Yuichi Terawaki, Takeshi Horikawa, Takako Kawanami, Yuriko Hamaguchi

Biochem Biophys Rep· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective androgen receptor modulator, S42 has anabolic and anti-catabolic effects on cultured myotubes.
Yoshimi Muta, Tomoko Tanaka, Yuriko Hamaguchi, Nobuya Hamanoue, Ryoko Motonaga

Biochem Biophys Rep· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells.
Hiroyuki Takahashi, Takashi Nomiyama, Yuichi Terawaki, Takako Kawanami, Yuriko Hamaguchi

J Atheroscler Thromb· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HMGA1a induces alternative splicing of estrogen receptor alpha in MCF-7 human breast cancer cells.
Kenji Ohe, Shinsuke Miyajima, Ichiro Abe, Tomoko Tanaka, Yuriko Hamaguchi

J Steroid Biochem Mol Biol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HMGA1a Induces Alternative Splicing of the α Gene by Trapping U1 snRNP to an Upstream Pseudo-5' Splice Site.
Kenji Ohe, Shinsuke Miyajima, Tomoko Tanaka, Yuriko Hamaguchi, Yoshihiro Harada

Front Mol Biosci· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective Androgen Receptor Modulator S42 Suppresses Prostate Cancer Cell Proliferation.
Takako Kawanami, Tomoko Tanaka, Yuriko Hamaguchi, Takashi Nomiyama, Hajime Nawata

Endocrinology· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-κB Activation.
Chikayo Iwaya, Takashi Nomiyama, Shiho Komatsu, Takako Kawanami, Yoko Tsutsumi, Yuriko Hamaguchi

Endocrinology· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Augmented Growth Hormone Secretion and Stat3 Phosphorylation in an Aryl Hydrocarbon Receptor Interacting Protein (AIP)-Disrupted Somatotroph Cell Line.
Takashi Fukuda, Tomoko Tanaka, Yuriko Hamaguchi, Takako Kawanami, Takashi Nomiyama

PLoS One· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
Yoko Tsutsumi, Takashi Nomiyama, Takako Kawanami, Yuriko Hamaguchi, Yuichi Terawaki

PLoS One· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.
Takashi Nomiyama, Takako Kawanami, Shinichiro Irie, Yuriko Hamaguchi, Yuichi Terawaki

Diabetes· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.
Yuichi Terawaki, Takashi Nomiyama, Takako Kawanami, Yuriko Hamaguchi, Hiroyuki Takahashi

Cardiovasc Diabetol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis